PT3116316T - Moduladores alostéricos da proteína do núcleo da hepatite b - Google Patents
Moduladores alostéricos da proteína do núcleo da hepatite bInfo
- Publication number
- PT3116316T PT3116316T PT15761201T PT15761201T PT3116316T PT 3116316 T PT3116316 T PT 3116316T PT 15761201 T PT15761201 T PT 15761201T PT 15761201 T PT15761201 T PT 15761201T PT 3116316 T PT3116316 T PT 3116316T
- Authority
- PT
- Portugal
- Prior art keywords
- hepatitis
- core protein
- allosteric modulators
- protein allosteric
- modulators
- Prior art date
Links
- 101710132601 Capsid protein Proteins 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/14—[b, e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/16—[b, f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461952467P | 2014-03-13 | 2014-03-13 | |
| US201462010025P | 2014-06-10 | 2014-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3116316T true PT3116316T (pt) | 2019-09-30 |
Family
ID=54072461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT15761201T PT3116316T (pt) | 2014-03-13 | 2015-03-13 | Moduladores alostéricos da proteína do núcleo da hepatite b |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10183936B2 (enExample) |
| EP (3) | EP3116316B1 (enExample) |
| JP (2) | JP6602311B2 (enExample) |
| KR (1) | KR102363174B1 (enExample) |
| CN (2) | CN110437153A (enExample) |
| AP (1) | AP2016009477A0 (enExample) |
| AU (2) | AU2015229174B2 (enExample) |
| CA (1) | CA2942533C (enExample) |
| CL (1) | CL2016002269A1 (enExample) |
| DK (1) | DK3116316T3 (enExample) |
| DO (1) | DOP2016000233A (enExample) |
| ES (1) | ES2748029T3 (enExample) |
| HR (1) | HRP20191444T1 (enExample) |
| HU (1) | HUE046567T2 (enExample) |
| IL (3) | IL247575B (enExample) |
| MX (2) | MX363600B (enExample) |
| PH (2) | PH12016501762B1 (enExample) |
| PL (1) | PL3116316T3 (enExample) |
| PT (1) | PT3116316T (enExample) |
| RS (1) | RS59430B1 (enExample) |
| SG (2) | SG10202001506UA (enExample) |
| WO (1) | WO2015138895A1 (enExample) |
| ZA (1) | ZA201606209B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5977837B2 (ja) | 2011-12-21 | 2016-08-24 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｂ型肝炎抗ウイルス剤 |
| CN104902885A (zh) | 2012-08-28 | 2015-09-09 | 爱尔兰詹森科学公司 | 氨磺酰基-芳基酰胺和其作为药物用于治疗乙型肝炎的用途 |
| BR112015020242A2 (pt) | 2013-02-28 | 2017-07-18 | Janssen Sciences Ireland Uc | sulfamoil-arilamidas e seu uso como medicamentos para o tratamento da hepatite b |
| JP6419155B2 (ja) | 2013-04-03 | 2018-11-07 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用 |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| MX366787B (es) | 2013-05-17 | 2019-07-23 | Janssen Sciences Ireland Uc | Derivados de sulfamoiltiofenamida y su uso como medicamentos para tratar la hepatitis b. |
| DK3024819T3 (en) | 2013-07-25 | 2018-06-06 | Janssen Sciences Ireland Uc | GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B |
| EA034448B1 (ru) | 2013-10-23 | 2020-02-10 | Янссен Сайенсиз Айрлэнд Юси | Производные карбоксамида и их применение в качестве медикаментов для лечения гепатита b |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| CN106232136A (zh) | 2014-02-05 | 2016-12-14 | 诺维拉治疗公司 | 用于治疗hbv感染的联合疗法 |
| CA2932551A1 (en) | 2014-02-06 | 2015-08-13 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| PL3116316T3 (pl) | 2014-03-13 | 2020-03-31 | Indiana University Research And Technology Corporation | Allosteryczne modulatory białka rdzeniowego wirusa zapalenia wątroby typu B |
| CA2980298A1 (en) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| CN108025034B (zh) * | 2015-07-15 | 2022-09-30 | 新加坡科技研究局 | 乙型肝炎病毒复制的调控 |
| TWI721016B (zh) * | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| CN108430971A (zh) | 2015-09-29 | 2018-08-21 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
| CN109640980A (zh) | 2016-04-15 | 2019-04-16 | 诺维拉治疗公司 | 包含壳体装配抑制剂的组合和方法 |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CA3037151A1 (en) * | 2016-09-15 | 2018-03-22 | Assembly Biosciences, Inc. | Hepatitis b core protein modulators |
| KR20190092374A (ko) * | 2016-10-03 | 2019-08-07 | 시질론 테라퓨틱스, 인크. | 화합물, 장치, 및 이의 용도 |
| US10821103B2 (en) | 2016-11-07 | 2020-11-03 | Arbutus Biopharma Corporation | Substituted pyridinone-containing trycyclic compounds, and methods using same |
| CN106632177A (zh) * | 2016-12-05 | 2017-05-10 | 万特制药(海南)有限公司 | 雷美替胺中间体的制备方法 |
| ES2874656T3 (es) * | 2017-02-23 | 2021-11-05 | Fujian Cosunter Pharmaceutical Co Ltd | Compuesto tricíclico y aplicaciones del mismo |
| AU2018227811A1 (en) | 2017-03-02 | 2019-09-19 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
| US11040965B2 (en) | 2017-03-13 | 2021-06-22 | Assembly Biosciences, Inc. | Process for making Hepatitis B core protein modulators |
| CA3056886A1 (en) | 2017-03-21 | 2018-09-27 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| BR112020001327A2 (pt) | 2017-07-21 | 2020-08-11 | Antabio Sas | compostos químicos |
| EA202091114A1 (ru) | 2017-11-02 | 2020-07-24 | Айкурис Гмбх Унд Ко. Кг | Новые высокоактивные пиразолопиперидин-замещенные индол-2-карбоксамиды, активные против вируса гепатита в (hbv) |
| MA50524A (fr) | 2017-11-02 | 2020-09-09 | Aicuris Gmbh & Co Kg | Nouveaux indole-2-carboxamides à substitution amino-thiazole hautement actifs agissant contre le virus de l'hépatite b (vhb) |
| EA202092171A1 (ru) | 2018-03-14 | 2020-12-01 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Схема дозирования модулятора сборки капсида |
| CA3099138A1 (en) * | 2018-05-03 | 2019-11-07 | Emory University | Modulators of orphan nuclear receptors for nash and other metabolic disorders |
| CN110627752B (zh) * | 2018-06-25 | 2021-08-17 | 新发药业有限公司 | 一种3-氨甲基四氢呋喃的制备方法 |
| CN108863884B (zh) * | 2018-07-26 | 2020-07-03 | 南京富润凯德生物医药有限公司 | 一种用dast试剂作为消除试剂合成共轭硝基烯取代系列衍生物的方法 |
| TWI869058B (zh) | 2018-07-27 | 2025-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 |
| WO2020038456A1 (zh) * | 2018-08-23 | 2020-02-27 | 福建广生堂药业股份有限公司 | 三并环类化合物的晶型及其应用 |
| UY38436A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| AR116948A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
| UY38439A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) |
| UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
| AR117188A1 (es) | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
| TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| MX2021010145A (es) | 2019-02-22 | 2021-09-14 | Janssen Sciences Ireland Unlimited Co | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. |
| JP2022533007A (ja) | 2019-04-30 | 2022-07-21 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Ｂ型肝炎ウイルス（ｈｂｖ）に対し活性な新規のインドリジン－２－カルボキサミド |
| KR20220003023A (ko) | 2019-04-30 | 2022-01-07 | 아이쿠리스 게엠베하 운트 코. 카게 | B형 간염 바이러스 (hbv)에 대해 활성인 신규 옥살릴 피페라진 |
| CU20210088A7 (es) | 2019-04-30 | 2022-06-06 | Aicuris Gmbh & Co Kg | Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| CA3138384A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv) |
| BR112021021454A2 (pt) | 2019-05-06 | 2021-12-21 | Janssen Sciences Ireland Unlimited Co | Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv |
| AU2020282318A1 (en) * | 2019-05-24 | 2021-12-02 | Assembly Biosciences, Inc. | Pharmaceutical compositions for the treatment of HBV |
| CN110526878A (zh) * | 2019-09-16 | 2019-12-03 | 成都睿智化学研究有限公司 | 一种2-(噁唑基)乙胺的制备方法 |
| CN111072551A (zh) * | 2019-12-30 | 2020-04-28 | 上海睿瓦科技有限公司 | 催化氢化一步法制取哌啶胺的方法 |
| WO2021216656A1 (en) * | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| CN113135848A (zh) * | 2021-04-26 | 2021-07-20 | 深圳市华先医药科技有限公司 | 一种巯基烯酯类化合物的制备方法 |
| CN113636960A (zh) * | 2021-08-24 | 2021-11-12 | 上海皓元医药股份有限公司 | 一种2-(氯磺酰基)环己烷-1-烯甲酸乙酯衍生物的制备方法 |
| CN113717080A (zh) * | 2021-10-09 | 2021-11-30 | 西安瑞联新材料股份有限公司 | 一种4-氯-2-氰基苯磺酰氯的合成方法 |
| CN115353479A (zh) * | 2022-07-27 | 2022-11-18 | 常州琦诺生物科技有限公司 | 一种5-溴-2-碘嘧啶的制备方法 |
| WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
| WO2025069039A1 (en) * | 2023-09-28 | 2025-04-03 | Rajaram Samant | An in situ process for the preparation of primary amine compounds |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1480553A (en) | 1976-06-03 | 1977-07-20 | Pfizer Ltd | Tricyclic sulphonamides |
| JPS58225074A (ja) | 1982-06-25 | 1983-12-27 | Chugai Pharmaceut Co Ltd | ジベンゾオキサゼピン誘導体 |
| GB9109557D0 (en) * | 1991-05-02 | 1991-06-26 | Wellcome Found | Chemical compounds |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| WO2005040355A2 (en) * | 2003-10-24 | 2005-05-06 | Exelixis, Inc. | Tao kinase modulators and methods of use |
| DE102004004928A1 (de) * | 2004-01-31 | 2005-08-18 | Bayer Healthcare Ag | Dibenzoxazepine II |
| WO2007047737A1 (en) * | 2005-10-17 | 2007-04-26 | Acadia Pharmaceuticals Inc. | Cb-1 modulating compounds and their use |
| WO2007056388A2 (en) | 2005-11-07 | 2007-05-18 | The General Hospital Corporation | Compositions and methods for modulating poly (adp-ribose) polymerase activity |
| WO2008036139A2 (en) | 2006-06-07 | 2008-03-27 | The Regents Of The University Of California | Inhibitors of mshc and homologs thereof, and methods of identifying same |
| WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| US8618090B2 (en) | 2008-07-23 | 2013-12-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the plasmodial surface anion channel as antimalarials |
| CN104530079B (zh) * | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| WO2012045194A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| EP2726459B1 (en) * | 2011-07-01 | 2019-09-11 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
| WO2013010069A1 (en) | 2011-07-13 | 2013-01-17 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
| JP6162144B2 (ja) | 2012-01-06 | 2017-07-19 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ４，４−二置換−１，４−ジヒドロピリミジン、及びｂ型肝炎の処置のための医薬としてのその使用 |
| CN104902885A (zh) | 2012-08-28 | 2015-09-09 | 爱尔兰詹森科学公司 | 氨磺酰基-芳基酰胺和其作为药物用于治疗乙型肝炎的用途 |
| PT2890683T (pt) | 2012-08-28 | 2017-01-17 | Janssen Sciences Ireland Uc | Derivados de sulfamoílo bicíclicos fundidos e a sua utilização como medicamentos para o tratamento da hepatite b |
| CA2881322A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| US20150292045A1 (en) | 2012-11-09 | 2015-10-15 | Indiana University Research And Technology Corporation | Alternative uses for hbv assembly effectors |
| SG10201900695PA (en) | 2012-12-06 | 2019-02-27 | Baruch S Blumberg Inst | Functionalized benzamide derivatives as antiviral agents against hbv infection |
| WO2014106019A2 (en) | 2012-12-27 | 2014-07-03 | Philadelphia Health & Education Corporation, D/B/A Drexel | Novel antiviral agents against hbv infection |
| RU2519546C1 (ru) | 2013-01-16 | 2014-06-10 | Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а |
| BR112015020242A2 (pt) | 2013-02-28 | 2017-07-18 | Janssen Sciences Ireland Uc | sulfamoil-arilamidas e seu uso como medicamentos para o tratamento da hepatite b |
| AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
| MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| JP6419155B2 (ja) | 2013-04-03 | 2018-11-07 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用 |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| MX366787B (es) | 2013-05-17 | 2019-07-23 | Janssen Sciences Ireland Uc | Derivados de sulfamoiltiofenamida y su uso como medicamentos para tratar la hepatitis b. |
| WO2014184328A1 (en) | 2013-05-17 | 2014-11-20 | F. Hoffmann-La Roche Ag | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| WO2014205138A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator and uses thereof |
| EP3027612B1 (en) | 2013-07-29 | 2018-10-10 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists |
| PL3116316T3 (pl) | 2014-03-13 | 2020-03-31 | Indiana University Research And Technology Corporation | Allosteryczne modulatory białka rdzeniowego wirusa zapalenia wątroby typu B |
| EA201692525A1 (ru) | 2014-06-10 | 2017-05-31 | Басф Се | Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов |
| TWI721016B (zh) | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| US10811219B2 (en) | 2018-08-07 | 2020-10-20 | Applied Materials Israel Ltd. | Method for evaluating a region of an object |
-
2015
- 2015-03-13 PL PL15761201T patent/PL3116316T3/pl unknown
- 2015-03-13 JP JP2016557019A patent/JP6602311B2/ja not_active Expired - Fee Related
- 2015-03-13 SG SG10202001506UA patent/SG10202001506UA/en unknown
- 2015-03-13 SG SG11201607268UA patent/SG11201607268UA/en unknown
- 2015-03-13 EP EP15761201.1A patent/EP3116316B1/en active Active
- 2015-03-13 CN CN201910710699.3A patent/CN110437153A/zh active Pending
- 2015-03-13 ES ES15761201T patent/ES2748029T3/es active Active
- 2015-03-13 KR KR1020167028057A patent/KR102363174B1/ko not_active Expired - Fee Related
- 2015-03-13 AU AU2015229174A patent/AU2015229174B2/en not_active Ceased
- 2015-03-13 EP EP21191660.6A patent/EP3974426A1/en not_active Withdrawn
- 2015-03-13 US US15/125,911 patent/US10183936B2/en active Active
- 2015-03-13 HU HUE15761201A patent/HUE046567T2/hu unknown
- 2015-03-13 HR HRP20191444 patent/HRP20191444T1/hr unknown
- 2015-03-13 MX MX2016011800A patent/MX363600B/es unknown
- 2015-03-13 DK DK15761201.1T patent/DK3116316T3/da active
- 2015-03-13 WO PCT/US2015/020444 patent/WO2015138895A1/en not_active Ceased
- 2015-03-13 PT PT15761201T patent/PT3116316T/pt unknown
- 2015-03-13 EP EP19184535.3A patent/EP3607950A3/en not_active Withdrawn
- 2015-03-13 CA CA2942533A patent/CA2942533C/en active Active
- 2015-03-13 PH PH1/2016/501762A patent/PH12016501762B1/en unknown
- 2015-03-13 PH PH1/2021/553231A patent/PH12021553231A1/en unknown
- 2015-03-13 RS RSP20191187 patent/RS59430B1/sr unknown
- 2015-03-13 AP AP2016009477A patent/AP2016009477A0/en unknown
- 2015-03-13 CN CN201580024580.0A patent/CN106413402B/zh active Active
-
2016
- 2016-08-31 IL IL247575A patent/IL247575B/en active IP Right Grant
- 2016-09-07 ZA ZA2016/06209A patent/ZA201606209B/en unknown
- 2016-09-07 DO DO2016000233A patent/DOP2016000233A/es unknown
- 2016-09-08 CL CL2016002269A patent/CL2016002269A1/es unknown
- 2016-09-12 MX MX2019003525A patent/MX2019003525A/es unknown
-
2018
- 2018-04-27 US US15/965,655 patent/US10947224B2/en active Active
-
2019
- 2019-04-26 JP JP2019085742A patent/JP2019151650A/ja not_active Withdrawn
- 2019-05-29 AU AU2019203754A patent/AU2019203754A1/en not_active Abandoned
-
2020
- 2020-03-08 IL IL273132A patent/IL273132B/en active IP Right Grant
-
2021
- 2021-01-21 US US17/154,721 patent/US20230019129A1/en not_active Abandoned
- 2021-04-18 IL IL282391A patent/IL282391A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282391A (en) | Allosteric modulators of hepatitis B core protein | |
| ZA201802456B (en) | Hepatitis b core protein modulators | |
| PL3303290T3 (pl) | Modulatory ROR-gamma | |
| PL3303293T3 (pl) | Modulatory ROR-gamma | |
| PL3303291T3 (pl) | Modulatory ROR-gamma | |
| GB201415344D0 (en) | Protein | |
| HUE067090T2 (hu) | Fehérje | |
| PL3319942T3 (pl) | MODULATORY ROR-GAMMA (RORγ) | |
| GB201401699D0 (en) | Protein | |
| GB2554821B (en) | Modulating processor core operations | |
| GB201412797D0 (en) | Proteins | |
| GB201412649D0 (en) | Proteins | |
| GB201412648D0 (en) | Proteins | |
| GB201412646D0 (en) | Proteins | |
| GB201414371D0 (en) | Protein modification | |
| GB201406894D0 (en) | Proteins | |
| GB201405955D0 (en) | Proteins | |
| GB201405952D0 (en) | Proteins | |
| GB201403914D0 (en) | Proteins | |
| GB201403915D0 (en) | Proteins | |
| GB201403913D0 (en) | Proteins | |
| GB201403912D0 (en) | Proteins | |
| GB201410682D0 (en) | Web-winding core | |
| GB201400215D0 (en) | Modulators |